5th Nov 2015 09:59
LONDON (Alliance News) - Quantum Pharma PLC on Thursday said its Colonis division has launched an in-licensed range of patented medical devices under the Mucodis name.
The devices are used to treat the side effects of cancer treatments including chemotherapy and radiotherapy, particularly the inflammation of mucusal membranes in the body, including the mouth and rectum.
The product will be marketed in the UK under the Mucodis name.
"We are excited to be making available the first product in the Mucodis range. This range has the potential to make a difference for patients living with the side effects of cancer treatment commonly triggered by radiotherapy and chemotherapy," said Andy Scaife, Quantum's chief executive.
Quantum shares were up 3.1% to 120.65 pence on Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Quantum Pharma